Interpore Is Seeking SEC Approval for $20-Million Public Stock Offering

Interpore International, a developer of synthetic bone graft material, is seeking permission to go public with the sale of up to $20 million worth of common stock.

In a filing with the Securities and Exchange Commission, the company said proceeds of the public offering of 2 million shares, to be priced at $8 to $10 a share, would be used to repay debt, fund clinical studies and research and development, and possibly to finance acquisitions.

Of the total shares, 500,000 would be offered by existing shareholders and 1.5 million would be sold by the company. Prudential Securities Inc., Sutro & Co. Inc. and Reich & Co. Inc. are underwriting the offering.